MLAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mesa Laboratories Inc (MLAB) is not a strong buy for a beginner investor with a long-term strategy at this moment. The stock's technical indicators are mixed, with no clear bullish momentum, and the company's financial performance shows a significant decline in net income and EPS despite slight revenue growth. Additionally, there are no significant positive catalysts or trading signals to suggest immediate upside potential. It is best to wait for stronger signals or improved financial performance before considering an investment.
The MACD is positive but contracting, suggesting weakening momentum. RSI is neutral at 42.633, indicating no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 99.509, with key support at 94.207 and resistance at 104.811.
Wells Fargo raised the price target to $94 from $83, citing strong Q3 revenue and margin expansion. Management is taking shareholder-friendly steps, and leverage is decreasing.
Net income and EPS have dropped significantly YoY (-316.59% and -309.68%, respectively). No recent news or significant trading trends from hedge funds or insiders. Congress trading data is also unavailable.
In Q3 2026, revenue increased by 3.64% YoY to $65,126,000, while net income dropped by -316.59% YoY to $3,630,000. EPS declined by -309.68% YoY to 0.65. Gross margin improved slightly by 1.45% YoY to 64.18%.
Wells Fargo maintains an Equal Weight rating with a price target increase to $94, citing solid Q3 performance and potential for valuation re-rating.
